[{"id":"0026ad65-8d38-4ca2-8a0a-0d46b06b1f05","acronym":"SWOG S1616","url":"https://clinicaltrials.gov/study/NCT03033576","created_at":"2021-01-18T14:55:53.378Z","updated_at":"2024-07-02T16:34:25.875Z","phase":"Phase 2","brief_title":"Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma","source_id_and_acronym":"NCT03033576 - SWOG S1616","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" CD8 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 10/23/2017","start_date":" 10/23/2017","primary_txt":" Primary completion: 09/19/2023","primary_completion_date":" 09/19/2023","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2024-06-14"},{"id":"310e9d9a-b69c-4442-97f5-d4d4ad2729a2","acronym":"NCI-2018-00918","url":"https://clinicaltrials.gov/study/NCT03449108","created_at":"2022-07-22T15:57:20.497Z","updated_at":"2024-07-02T16:35:02.803Z","phase":"Phase 2","brief_title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","source_id_and_acronym":"NCT03449108 - NCI-2018-00918","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • CD8 • CD28 • CD27","pipe":" | ","alterations":" CD8 expression • CD28 expression","tags":["HER-2 • CD8 • CD28 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/27/2018","start_date":" 04/27/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-17"},{"id":"2af63127-3115-4ddf-9da7-0032fefe8e92","acronym":"iPREDICT","url":"https://clinicaltrials.gov/study/NCT05013099","created_at":"2021-08-19T14:52:55.130Z","updated_at":"2024-07-02T16:35:10.176Z","phase":"Phase 2","brief_title":"Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies","source_id_and_acronym":"NCT05013099 - iPREDICT","lead_sponsor":"ImaginAb, Inc.","biomarkers":" PD-L1 • KRAS • CD8 • PD-1","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression","tags":["PD-L1 • KRAS • CD8 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-04-11"},{"id":"cfc6d13e-93fd-4b7f-b2c6-5aa01c31d105","acronym":"","url":"https://clinicaltrials.gov/study/NCT06325423","created_at":"2024-03-22T23:35:41.122Z","updated_at":"2024-07-02T16:35:12.759Z","phase":"","brief_title":"Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer","source_id_and_acronym":"NCT06325423","lead_sponsor":"Assiut University","biomarkers":" CD8","pipe":" | ","alterations":" CD8 expression","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-26"},{"id":"0367ee49-0836-46f6-bf51-056530d84456","acronym":"COLEMAN","url":"https://clinicaltrials.gov/study/NCT05029791","created_at":"2021-09-01T14:52:58.063Z","updated_at":"2024-07-02T16:35:26.104Z","phase":"","brief_title":"Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients","source_id_and_acronym":"NCT05029791 - COLEMAN","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" CD8 • ZEB1","pipe":" | ","alterations":" CD8 expression • ZEB1 expression","tags":["CD8 • ZEB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • ZEB1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 11/18/2031","primary_completion_date":" 11/18/2031","study_txt":" Completion: 11/18/2031","study_completion_date":" 11/18/2031","last_update_posted":"2023-12-15"},{"id":"3e645071-4216-4aec-a0bd-0e6e40f1d02a","acronym":"S1607","url":"https://clinicaltrials.gov/study/NCT02965716","created_at":"2021-01-18T14:34:36.597Z","updated_at":"2024-07-02T16:35:26.748Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT02965716 - S1607","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86","pipe":" | ","alterations":" CD8 expression","tags":["TMB • CD8 • PD-1 • CD14 • FOXP3 • CD80 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/05/2018","start_date":" 06/05/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 11/05/2024","study_completion_date":" 11/05/2024","last_update_posted":"2023-12-08"},{"id":"2f64949b-56d2-4517-8a8d-e52f407e983c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03559413","created_at":"2021-01-18T17:31:11.379Z","updated_at":"2024-07-02T16:35:27.228Z","phase":"Phase 1/2","brief_title":"Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL","source_id_and_acronym":"NCT03559413","lead_sponsor":"University Children's Hospital Tuebingen","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" CD8 expression • CD4 expression","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-12-04"},{"id":"69708668-cfc0-4439-a660-502e583a10e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05483075","created_at":"2022-08-01T14:54:50.589Z","updated_at":"2024-07-02T16:35:29.781Z","phase":"","brief_title":"Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer","source_id_and_acronym":"NCT05483075","lead_sponsor":"NYU Langone Health","biomarkers":" CD8 • GZMB","pipe":" | ","alterations":" CD8 expression • CD8 positive","tags":["CD8 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD8 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-11-09"},{"id":"fa8a97f1-cabc-4bf2-8fa9-208f8cb378d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04977024","created_at":"2021-07-26T17:53:28.425Z","updated_at":"2024-07-02T16:35:30.225Z","phase":"Phase 2","brief_title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","source_id_and_acronym":"NCT04977024","lead_sponsor":"GeoVax, Inc.","biomarkers":" CD8 • PD-1 • IFNG • CD4 • TNFRSF9 • ACE2","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • PD-1 • IFNG • CD4 • TNFRSF9 • ACE2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 09/27/2021","start_date":" 09/27/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-11-06"},{"id":"d5870014-be37-4a8f-b38f-acf430db9ed2","acronym":"TIBIOP-LMC","url":"https://clinicaltrials.gov/study/NCT04645706","created_at":"2021-01-19T20:39:33.885Z","updated_at":"2024-07-02T16:35:40.883Z","phase":"","brief_title":"Innate T Cells and TKI Discontinuation","source_id_and_acronym":"NCT04645706 - TIBIOP-LMC","lead_sponsor":"Poitiers University Hospital","biomarkers":" CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20","pipe":" | ","alterations":" CD8 expression • IFNG expression","tags":["CD8 • IFNG • IL2RA • CCR7 • ITGA4 • PRF1 • B3GAT1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-08-04"},{"id":"7ac8d8f5-8a41-40b1-9240-a2b0c34c13bd","acronym":"DECIDE","url":"https://clinicaltrials.gov/study/NCT03958240","created_at":"2021-01-18T19:28:44.172Z","updated_at":"2024-07-02T16:35:42.158Z","phase":"","brief_title":"Deciphering Mechanisms Underlying Cancer Immunogenicity","source_id_and_acronym":"NCT03958240 - DECIDE","lead_sponsor":"Institut Claudius Regaud","biomarkers":" PD-1 • CD4","pipe":" | ","alterations":" CD8 expression","tags":["PD-1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 01/17/2020","start_date":" 01/17/2020","primary_txt":" Primary completion: 09/01/2029","primary_completion_date":" 09/01/2029","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2023-07-24"},{"id":"ac5acaad-e81c-452a-8add-e324e99252a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02795429","created_at":"2021-06-15T00:55:17.811Z","updated_at":"2024-07-02T16:35:44.225Z","phase":"Phase 1/2","brief_title":"Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC","source_id_and_acronym":"NCT02795429","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" CD8 expression","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tabrecta (capmatinib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 06/15/2016","start_date":" 06/15/2016","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/24/2021","study_completion_date":" 06/24/2021","last_update_posted":"2023-06-30"},{"id":"58ad1cf0-b0ae-467d-991a-a5d900291a36","acronym":"IMMUVIX","url":"https://clinicaltrials.gov/study/NCT03255252","created_at":"2021-01-18T16:04:49.386Z","updated_at":"2024-07-02T16:35:46.214Z","phase":"Phase 2","brief_title":"Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy","source_id_and_acronym":"NCT03255252 - IMMUVIX","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" CD8 • PD-1 • HAVCR2 • CD4 • ENTPD1","pipe":" | ","alterations":" PD-1 expression • CD8 expression • ENTPD1 expression","tags":["CD8 • PD-1 • HAVCR2 • CD4 • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • CD8 expression • ENTPD1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/15/2017","start_date":" 07/15/2017","primary_txt":" Primary completion: 06/16/2022","primary_completion_date":" 06/16/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-06-07"},{"id":"b9b5dae3-5791-48c7-b400-aad98b6dbf14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02605967","created_at":"2021-01-18T12:39:30.324Z","updated_at":"2024-07-02T16:36:17.276Z","phase":"Phase 2","brief_title":"Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","source_id_and_acronym":"NCT02605967","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1 • CD8 • IFNG • IL6 • TNFA • CD4","pipe":" | ","alterations":" CD8 expression","tags":["PD-L1 • CD8 • IFNG • IL6 • TNFA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 04/20/2016","start_date":" 04/20/2016","primary_txt":" Primary completion: 11/05/2019","primary_completion_date":" 11/05/2019","study_txt":" Completion: 02/19/2021","study_completion_date":" 02/19/2021","last_update_posted":"2022-02-10"},{"id":"b5ce9f6f-90bd-4e6c-8af0-4771e28aea48","acronym":"","url":"https://clinicaltrials.gov/study/NCT03021993","created_at":"2021-01-18T14:52:12.866Z","updated_at":"2025-02-25T14:37:08.309Z","phase":"Phase 2","brief_title":"Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer","source_id_and_acronym":"NCT03021993","lead_sponsor":"Medical University of South Carolina","biomarkers":" CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3","pipe":" | ","alterations":" CD8 expression • IFNG expression • IL2 expression","tags":["CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression • IL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/30/2017","start_date":" 05/30/2017","primary_txt":" Primary completion: 11/15/2021","primary_completion_date":" 11/15/2021","study_txt":" Completion: 11/15/2021","study_completion_date":" 11/15/2021","last_update_posted":"2021-12-13"},{"id":"f8bc02f5-25c4-4544-a89b-128dd617c0b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05098990","created_at":"2021-10-29T14:53:11.320Z","updated_at":"2024-07-02T16:36:22.198Z","phase":"Phase 4","brief_title":"Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC","source_id_and_acronym":"NCT05098990","lead_sponsor":"China Resources Sanjiu Medical \u0026 Pharmaceutical Co., Ltd.","biomarkers":" EGFR • ALK • ROS1 • CD8 • CD4","pipe":" | ","alterations":" CD8 expression","tags":["EGFR • ALK • ROS1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 328","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 08/15/2024","study_completion_date":" 08/15/2024","last_update_posted":"2021-10-29"},{"id":"8de56a8f-2ad2-4af5-bc14-736a9721360e","acronym":"ANSR-PDAC","url":"https://clinicaltrials.gov/study/NCT04915417","created_at":"2021-06-07T15:53:25.453Z","updated_at":"2024-07-02T16:36:28.778Z","phase":"","brief_title":"Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT04915417 - ANSR-PDAC","lead_sponsor":"Lawson Health Research Institute","biomarkers":" PD-L1 • CD8 • CEACAM5","pipe":" | ","alterations":" PD-L1 expression • CD8 expression • CEACAM5 expression","tags":["PD-L1 • CD8 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD8 expression • CEACAM5 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2021-06-22"},{"id":"be90799f-136d-496d-adb9-c7981cf760f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04792437","created_at":"2021-03-11T13:52:40.593Z","updated_at":"2024-07-02T16:36:32.874Z","phase":"","brief_title":"Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data","source_id_and_acronym":"NCT04792437","lead_sponsor":"Yu Yao, MD","biomarkers":" PD-L1 • TMB • CD8 • TERT • PD-1 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD8 expression • TERT mutation","tags":["PD-L1 • TMB • CD8 • TERT • PD-1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD8 expression • TERT mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2021-03-24"},{"id":"cca55acd-fe7d-4fd1-a867-4d67afcb638c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02179515","created_at":"2021-01-18T10:09:59.893Z","updated_at":"2024-07-02T16:36:35.567Z","phase":"Phase 1","brief_title":"Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)","source_id_and_acronym":"NCT02179515","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IFNG • TNFA • IL2 • ICAM1 • IL10 • CD27 • LAMP1 • CD58 • CD40LG • IL4","pipe":" | ","alterations":" ER positive • EGFR mutation • CD8 expression","tags":["CD8 • IFNG • TNFA • IL2 • ICAM1 • IL10 • CD27 • LAMP1 • CD58 • CD40LG • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • EGFR mutation • CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BN-Brachyury"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 06/28/2014","start_date":" 06/28/2014","primary_txt":" Primary completion: 04/06/2017","primary_completion_date":" 04/06/2017","study_txt":" Completion: 02/28/2018","study_completion_date":" 02/28/2018","last_update_posted":"2021-01-26"},{"id":"dbb9d198-ed28-4421-824d-ac33880d2023","acronym":"","url":"https://clinicaltrials.gov/study/NCT03289533","created_at":"2021-01-18T16:15:03.946Z","updated_at":"2024-07-02T16:36:41.317Z","phase":"Phase 1b","brief_title":"A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)","source_id_and_acronym":"NCT03289533","lead_sponsor":"Pfizer","biomarkers":" PD-L1 • CD8 • AFP","pipe":" | ","alterations":" CD8 expression","tags":["PD-L1 • CD8 • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • axitinib"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/08/2017","start_date":" 09/08/2017","primary_txt":" Primary completion: 08/27/2019","primary_completion_date":" 08/27/2019","study_txt":" Completion: 10/25/2019","study_completion_date":" 10/25/2019","last_update_posted":"2020-09-04"},{"id":"60e1151a-f1e8-4130-93c4-041a8babe961","acronym":"tumorimmunity","url":"https://clinicaltrials.gov/study/NCT04518579","created_at":"2021-01-18T21:38:59.735Z","updated_at":"2024-07-02T16:36:41.742Z","phase":"","brief_title":"Epidural-inhalational Versus Epidural-intravenous Anaesthesia on Anti-tumor Immunity in Patients With Cancer Colon","source_id_and_acronym":"NCT04518579 - tumorimmunity","lead_sponsor":"South Egypt Cancer Institute","biomarkers":" CD8 • NCAM1 • VEGFC","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • NCAM1 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 04/15/2018","start_date":" 04/15/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 08/01/2020","study_completion_date":" 08/01/2020","last_update_posted":"2020-08-21"},{"id":"e90d90e5-33e6-4be3-bd2c-8d8dccd30023","acronym":"","url":"https://clinicaltrials.gov/study/NCT04355806","created_at":"2021-01-18T21:03:23.571Z","updated_at":"2024-07-02T16:36:45.824Z","phase":"","brief_title":"Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors","source_id_and_acronym":"NCT04355806","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5","pipe":" | ","alterations":" CD8 expression","tags":["CD8 • IFNG • IL6 • TNFA • CXCL8 • CXCL10 • CD4 • CD69 • IL2 • IL10 • CCL2 • CSF2 • IL13 • IL1B • IL4 • IL5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2020-04-21"},{"id":"862ecf2e-2fc1-4313-b0a7-f08c9d1930b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03167853","created_at":"2021-01-18T15:37:09.579Z","updated_at":"2024-07-02T16:36:58.728Z","phase":"Phase 1","brief_title":"Study of JS001 in Patients With Advanced Neuroendocrine Tumors","source_id_and_acronym":"NCT03167853","lead_sponsor":"Peking University","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression • CD8 expression","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 04/06/2017","start_date":" 04/06/2017","primary_txt":" Primary completion: 12/11/2018","primary_completion_date":" 12/11/2018","study_txt":" Completion: 05/11/2019","study_completion_date":" 05/11/2019","last_update_posted":"2019-06-21"},{"id":"4431da00-8b6b-4669-ad59-700db60c1aee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03559803","created_at":"2021-01-18T17:31:17.007Z","updated_at":"2024-07-02T16:37:03.628Z","phase":"","brief_title":"A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer","source_id_and_acronym":"NCT03559803","lead_sponsor":"Sichuan University","biomarkers":" PD-L1 • CD8 • PD-1 • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • CD8 expression","tags":["PD-L1 • CD8 • PD-1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Unknown status","enrollment":" Enrollment 58","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-01-22"}]